A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease
- PMID: 21335973
- DOI: 10.1159/000324438
A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease
Abstract
Background/aims: Behavioural and psychological symptoms (BPSD) are frequent in people with Alzheimer's disease and cause considerable stress to patients and their carers. Antipsychotics have been widely used as a first-line treatment, resulting in an estimated 1,800 excess strokes and 1,600 excess deaths in the UK alone. Safe and effective alternatives are urgently needed. Based upon preliminary evidence from clinical trials, aromatherapy with melissa oil may be such an alternative, but initial studies have been modest in size, and adequate blinding has been problematic. Our objective was to assess the efficacy of melissa aromatherapy in the treatment of agitation in people with Alzheimer's disease in an adequately powered and robustly blinded randomized controlled trial comparing it with donepezil, an anticholinesterase drug used with some benefit to treat BPSD.
Methods and findings: The study was a double-blind parallel-group placebo-controlled randomized trial across 3 specialist old age psychiatry centres in England. Participants had probable or possible Alzheimer's disease, were resident in a care home, had clinically significant agitation (defined as a score of 39 or above on the Cohen Mansfield Agitation Inventory) and were free of antipsychotics and/or anticholinesterase for at least 2 weeks. Participants were allocated to 1 of 3 groups: placebo medication and active aromatherapy; active medication and placebo aromatherapy or placebo of both.
Main outcome: The primary outcome measure was reduction in agitation as assessed by the Pittsburgh Agitation Scale (PAS) at 4 weeks. This is an observational scale, and raters were required to wear nose clips to ensure that full blinding was maintained. The PAS, Neuropsychiatric Inventory (NPI; another measure of BPSD) and other outcome measures were completed at baseline, 4-week and 12-week follow-ups. 114 participants were randomized, of whom 94 completed the week 4 assessment and 81 completed the week 12 assessment. Aromatherapy and donepezil were well tolerated. There were no significant differences between aromatherapy, donepezil and placebo at week 4 and week 12, but importantly there were substantial improvements in all 3 groups with an 18% improvement in the PAS and a 37% improvement in the NPI over 12 weeks.
Conclusion: When assessed using a rigorous design which ensures blinding of treatment arms, there is no evidence that melissa aromatherapy is superior to placebo or donepezil, in the treatment of agitation in people with Alzheimer's disease. However, the sizeable improvement in the placebo group emphasizes the potential non-specific benefits of touch and interaction in the treatment of agitation in people with Alzheimer's disease.
Copyright © 2011 S. Karger AG, Basel.
Similar articles
-
Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.Dement Geriatr Cogn Disord. 2009;27(3):232-9. doi: 10.1159/000203887. Epub 2009 Feb 25. Dement Geriatr Cogn Disord. 2009. PMID: 19246907 Clinical Trial.
-
Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69. doi: 10.1002/gps.1325. Int J Geriatr Psychiatry. 2005. PMID: 15920715 Clinical Trial.
-
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.J Am Geriatr Soc. 2001 Dec;49(12):1590-9. J Am Geriatr Soc. 2001. PMID: 11843990 Clinical Trial.
-
Donepezil for Alzheimer's disease.Expert Rev Neurother. 2007 Oct;7(10):1243-9. doi: 10.1586/14737175.7.10.1243. Expert Rev Neurother. 2007. PMID: 17939763 Review.
-
[[Donepezil : a new option in the treatment of Alzheimer's disease] ONEPA].Rev Med Univ Navarra. 1998 Apr-Jun;42(2):109-18. Rev Med Univ Navarra. 1998. PMID: 10420948 Review. Spanish. No abstract available.
Cited by
-
The possible "calming effect" of subchronic supplementation of a standardised phospholipid carrier-based Melissa officinalis L. extract in healthy adults with emotional distress and poor sleep conditions: results from a prospective, randomised, double-blinded, placebo-controlled clinical trial.Front Pharmacol. 2023 Oct 19;14:1250560. doi: 10.3389/fphar.2023.1250560. eCollection 2023. Front Pharmacol. 2023. PMID: 37927585 Free PMC article.
-
Therapeutic potential of aromatic plant extracts in Alzheimer's disease: Comprehensive review of their underlying mechanisms.CNS Neurosci Ther. 2023 Aug;29(8):2045-2059. doi: 10.1111/cns.14234. Epub 2023 Apr 30. CNS Neurosci Ther. 2023. PMID: 37122144 Free PMC article. Review.
-
Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis.Front Aging Neurosci. 2023 Mar 3;15:1103039. doi: 10.3389/fnagi.2023.1103039. eCollection 2023. Front Aging Neurosci. 2023. PMID: 36936502 Free PMC article.
-
Medicinal Plants Used for Anxiety, Depression, or Stress Treatment: An Update.Molecules. 2022 Sep 15;27(18):6021. doi: 10.3390/molecules27186021. Molecules. 2022. PMID: 36144755 Free PMC article. Review.
-
Assess of Combinations of Non-Pharmacological Interventions for the Reduction of Irritability in Patients with Dementia and their Caregivers: A Cross-Over RCT.Brain Sci. 2022 May 26;12(6):691. doi: 10.3390/brainsci12060691. Brain Sci. 2022. PMID: 35741577 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical